This study compared the bioavailability of DFN-15, a novel oral liquid formulation of celecoxib, relative to celecoxib 400-mg oral capsules and determined the dose proportionality of DFN-15.

After administration of DFN-15 120, 180, and 240 mg, maximum observed plasma concentration (C max) values (1062–1933 ng/ml) were higher than for the 400-mg oral capsules (611 ng/ml), and the median time to peak concentration (T max) was within 1 h for DFN-15 and 2.5 h for the oral capsules.

DFN-15 is being evaluated as an acute treatment for migraine based on its faster absorption and greater bioavailability than celecoxib 400-mg oral capsules.